Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -60.22% | 86.93% | -34,000.00% | 81.41% | -23.98% |
| Total Depreciation and Amortization | 0.00% | -11.35% | -13.19% | -14.86% | -19.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.76% | -97.27% | 176.22% | -87.18% | 0.00% |
| Change in Net Operating Assets | -36.45% | 149.63% | 32.23% | 93.39% | 393.15% |
| Cash from Operations | -130.81% | 38.97% | 3.68% | 60.61% | 2,914.29% |
| Capital Expenditure | 35.71% | 25.00% | -1.89% | -30.56% | 20.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.18% | 73.17% | 63.33% | 43.48% | -254.55% |
| Cash from Investing | 66.13% | 53.62% | 21.69% | -1.69% | -182.67% |
| Total Debt Issued | -- | -- | -- | -100.00% | 525.00% |
| Total Debt Repaid | 99.83% | -100.00% | 99.51% | 101.56% | -199.00% |
| Issuance of Common Stock | -- | 3.70% | -- | -79.31% | -- |
| Repurchase of Common Stock | 33.33% | -- | 50.00% | 0.00% | 90.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,875.00% | -- |
| Cash from Financing | -100.53% | -15.38% | -122.06% | -490.48% | 1,912.90% |
| Foreign Exchange rate Adjustments | -- | -83.33% | -200.00% | 114.29% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.66% | 46.82% | -132.11% | -266.67% | 726.74% |